Rajinder L Singh

US Patent:

6387920, May 14, 2002

Filed:

Apr 11, 2001

Appl. No.:

09/833392

Inventors:

Verena D. Huebner - Benicia CA
Xiaodong Lin - Walnut Creek CA
Ian James - Rowville, AU
Liya Chen - East Brunswick NJ
Manoj Desai - Pleasant Hill CA
Jennifer C. Moore - Emeryville CA
Beata Krywult - Armadale, AU
Thayalan Navaratnam - San Leandro CA
Rajinder Singh - San Francisco CA
Rob Trainor - Murrumbeena, AU
Liang Wang - Lafayette CA

Assignee:

Chiron Corporation - Emeryville CA

International Classification:

A61K 3144

US Classification:

514293, 546 83

Abstract:

Isoxazole estrogen receptor agonist and antagonist compounds having unexpected and surprising activity in modulating estrogen receptor activity are described. In addition, methods and compositions for treating or preventing estrogen receptor-mediated disorders are disclosed. The compounds, methods, and compositions of the invention have utility in preventing or treating estrogen receptor-mediated disorders such as osteoporosis, breast and endometrial cancers, atherosclerosis, and Alzheimers disease.

US Patent:

6727273, Apr 27, 2004

Filed:

Sep 18, 2001

Appl. No.:

09/954039

Inventors:

Verena D. Huebner - Benicia CA
Xiaodong Lin - Walnut Creek CA
Ian James - Rowville, AU
Liya Chen - East Brunswick NJ
Manoj Desai - Pleasant Hill CA
Beata Krywult - Armadale, AU
Rajinder Singh - San Francisco CA
Liang Wang - Lafayette CA

Assignee:

Chiron Corporation - Emeryville CA

International Classification:

A61K 31416

US Classification:

514406, 5483591

Abstract:

Estrogen receptor-modulating pyrazole compounds are described in addition to methods and compositions for treating or preventing estrogen receptor-mediated disorders. The compounds described have been found to have unexpected and surprising activity in modulating estrogen receptor activity. Thus, the compounds of the present invention have utility in preventing or treating estrogen receptor-mediated disorders such as osteoporosis, breast and endometrial cancers, atherosclerosis, and Alzheimers disease.

US Patent:

6743815, Jun 1, 2004

Filed:

Apr 25, 2002

Appl. No.:

10/134302

Inventors:

Verena D. Huebner - Benicia CA
Xiaodong Lin - Walnut Creek CA
Ian James - Rowville, AU
Liya Chen - East Brunswick NJ
Manoj Desai - Pleasant Hill CA
Jennifer C. Moore - Emeryville CA
Beata Krywult - Armadale, AU
Thayalan Navaratnam - San Leandro CA
Rajinder Singh - San Francisco CA
Rob Trainor - Murrumbeena, AU
Liang Wang - Lafayette CA

Assignee:

Chiron Corporation - Emeryville CA

International Classification:

A61K 3142

US Classification:

514378, 548240

Abstract:

Isoxazole estrogen receptor agonist and antagonist compounds having unexpected and surprising activity in modulating estrogen receptor activity are described. In addition, methods and compositions for treating or preventing estrogen receptor-mediated disorders are disclosed. The compounds, methods, and compositions of the invention have utility in preventing or treating estrogen receptor-mediated disorders such as osteoporosis, breast and endometrial cancers, atherosclerosis, and Alzheimers disease.

US Patent:

6759538, Jul 6, 2004

Filed:

Nov 1, 2002

Appl. No.:

10/286017

Inventors:

Rajinder Singh - Walnut Creek CA
Dane Goff - Redwood CA
Henry Lu - Foster City CA
Thomas Sun - Fremont CA

Assignee:

Rigel Pharmaceuticals, Inc. - South San Francisco CA

International Classification:

A61P 4300

US Classification:

548240, 514400, 514406, 5482676, 5483751, 5483381

Abstract:

The present invention relates to substituted diphenyl heterocycle compounds and pharmaceutical compositions thereof that inhibit replication of HCV virus. The present invention also relates to the use of the compounds and/or compositions to inhibit HCV replication and/or proliferation and to treat or prevent HCV infections.

US Patent:

6869969, Mar 22, 2005

Filed:

Nov 13, 2003

Appl. No.:

10/713621

Inventors:

Verena D. Huebner - Benicia CA, US
Xiaodong Lin - Walnut Creek CA, US
Ian James - Rowville, AU
Liya Chen - East Brunswick NJ, US
Manoj Desai - Pleasant Hill CA, US
Jennifer C. Moore - Emeryville CA, US
Beata Krywult - Armadale, AU
Thayalan Navaratnam - San Leandro CA, US
Rajinder Singh - San Francisco CA, US
Rob Trainor - Murrumbeena, AU
Liang Wang - Lafayette CA, US

Assignee:

Chiron Corporation - Emeryville CA

International Classification:

A61K031/42
C07D261/02
C07D261/06

US Classification:

514378, 548240, 548247

Abstract:

Isoxazole estrogen receptor agonist and antagonist compounds having unexpected and surprising activity in modulating estrogen receptor activity are described. In addition, methods and compositions for treating or preventing estrogen receptor-mediated disorders are disclosed. The compounds, methods, and compositions of the invention have utility in preventing or treating estrogen receptor-mediated disorders such as osteoporosis, breast and endometrial cancers, atherosclerosis, and Alzheimer's disease.

US Patent:

7060827, Jun 13, 2006

Filed:

Jun 1, 2004

Appl. No.:

10/858343

Inventors:

Rajinder Singh - Belmont CA, US
Ankush Argade - Foster City CA, US
Donald Payan - Hillsborough CA, US
Susan Molineaux - San Mateo CA, US
Sacha J. Holland - San Francisco CA, US
Jeffrey Clough - Redwood City CA, US
Holger Keim - Menlo Park CA, US
Somasekhar Bhamidipati - Foster City CA, US
Catherine Sylvain - Burlingame CA, US
Hui Li - Millbrae CA, US
Alexander B. Rossi - San Francisco CA, US

Assignee:

Rigel Pharmaceuticals, Inc. - South San Francisco CA

International Classification:

C07D 239/02

US Classification:

544323, 544324, 544320

Abstract:

The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.

US Patent:

7115642, Oct 3, 2006

Filed:

May 3, 2004

Appl. No.:

10/838133

Inventors:

Rajinder Singh - Belmont CA, US
Dane Goff - Redwood City CA, US
John J. Partridge - Chapel Hill NC, US

Assignee:

Rigel Pharmaceuticals, Inc. - South San Francisco CA

International Classification:

A61K 31/415
C07D 207/02

US Classification:

514378, 5142368, 544137, 546208, 548240

Abstract:

The present invention relates to substituted diphenyl heterocycle compounds and pharmaceutical compositions thereof that inhibit replication of HCV virus. The present invention also relates to the use of the compounds and/or compositions to inhibit HCV replication and/or proliferation and to treat or prevent HCV infections.

US Patent:

7122542, Oct 17, 2006

Filed:

Jul 30, 2004

Appl. No.:

10/903870

Inventors:

Rajinder Singh - Belmont CA, US
Ankush Argade - Foster City CA, US
Hui Li - Millbrae CA, US
Somasekhar Bhamidipati - Foster City CA, US
David Carroll - San Francisco CA, US
Catherine Sylvain - Burligame CA, US
Jeffrey Clough - Redwood City CA, US
Holger Keim - Menlo Park CA, US

Assignee:

Rigel Pharmaceuticals, Inc. - South San Francisco CA

International Classification:

A61K 19/02
A61K 31/535
C07D 268/36

US Classification:

5142305, 544105

Abstract:

The present invention provides methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds, as well as methods of treating, preventing or ameliorating symptoms associated with such diseases. Specific examples of autoimmune diseases that can be treated or prevented with the compounds include rheumatoid arthritis and/or its associated symptoms, systemic lups erythematosis and/or its associated symptoms and multiple sclerosis and/or its associated symptoms.